Brainstorm Cell Therapeutics Inc. Stock
Stocks
BCLI
US10501E3009
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
OTC Markets
15:20:49 2026-09-11 EDT
|
5-day change | 1st Jan Change | ||
| 1.080 USD | +4.85% |
|
+2.86% | +95.30% |
| Market Cap | 11.92M 10.27M 9.72M 8.81M 16.53M 1.14B 16.62M 115M 44.4M 579M 44.76M 43.78M 1.83B | P/E 2026 * |
-1.19x | P/E 2027 * | -1.06x |
|---|---|---|---|---|---|
| Enterprise Value | 11.92M 10.27M 9.72M 8.81M 16.53M 1.14B 16.62M 115M 44.4M 579M 44.76M 43.78M 1.83B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
88.82% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Brainstorm Cell Therapeutics Inc.
| 1 day | +4.85% | ||
| 1 week | +2.86% | ||
| Current month | +1.41% | ||
| 1 month | +27.06% | ||
| 3 months | +40.11% | ||
| 6 months | +45.95% | ||
| Current year | +95.30% |
| 1 week | 0.98 |  | 1.08 |
| 1 month | 0.8 | | 1.49 |
| Current year | 0.46 | | 1.69 |
| 1 year | 0.46 | | 1.69 |
| 3 years | 0.46 | | 20.25 |
| 5 years | 0.46 | | 70.5 |
| 10 years | 0.46 | | 269.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
Chaim Lebovits
CEO | Chief Executive Officer | 55 | 2013-07-31 |
Peter Pitts
LAW | General Counsel | 67 | 2026-07-23 |
Alla Patlis
DFI | Director of Finance/CFO | 39 | 2021-08-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Irit Arbel
CHM | Chairman | 66 | 2014-04-24 |
Uri Yablonka
BRD | Director/Board Member | 49 | 2014-06-05 |
| Director/Board Member | 63 | 2018-02-04 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 7/24/26 | Free | Chairman | 900,000 | 8.1560% | ||
| 7/24/26 | Free | Chairman | 100,000 | 0.9062% | ||
| 5/25/26 | Other | Director | 150,000 | 1.3593% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.85% | +2.86% | +52.01% | -94.63% | 11.92M | |
| -0.71% | -6.35% | -4.87% | +9.03% | 45.48B | |
| +0.21% | -2.98% | +340.68% | +519.93% | 43.69B | |
| +1.74% | -2.24% | +37.28% | +21.57% | 43.09B | |
| +1.38% | -3.28% | +3.23% | +65.60% | 39.4B | |
| -1.44% | -5.26% | +8.78% | +36.85% | 31.91B | |
| +0.87% | -2.60% | - | - | 17.31B | |
| +0.75% | -0.64% | +18.07% | +110.32% | 16.4B | |
| -0.31% | -2.78% | +10.47% | +30.49% | 14.24B | |
| +1.93% | -3.55% | +74.20% | +39.37% | 13.28B | |
| Average | +0.93% | -2.93% | +59.98% | +82.06% | 26.48B | |
| Weighted average by Cap. | +0.41% | -3.67% | +73.16% | +123.56% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -13.78M -11.87M -11.24M -10.19M -19.11M -1.32B -19.21M -133M -51.33M -670M -51.74M -50.6M -2.12B | -29.97M -25.82M -24.45M -22.16M -41.58M -2.86B -41.79M -290M -112M -1.46B -113M -110M -4.6B |
| Net Debt | - | - |
Employees
19
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-11 | US$1.080 | +4.85% | 42,883 |
| 26-09-10 | US$1.030 | +3.00% | 17,947 |
| 26-09-09 | US$1.000 | +1.01% | 6,898 |
| 26-09-08 | US$0.9900 | -5.71% | 6,890 |
| 26-09-04 | US$1.050 | -1.87% | 7,211 |
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1.080
Average target price
-
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BCLI Stock
Select your edition
All financial news and data tailored to specific country editions
